SHINE Technologies receives EU CMA for Ilumira Lu-177 radioisotope

SHINE Technologies has secured a CMA in Europe for its radioisotope product Ilumira, allowing it to sell Lu-177 across the EU. The development coincides with several steps by SHINE Technologies to broaden its position in nuclear medicine. The regulatory clearance enables access to a major market for the use of Lu-177 in targeted radioligand therapies. Credit: Gorodenkoff / Shutterstock.com. Next-generation fusion specialist SHINE Technologies has secured centralised marketing authorisation (CMA) in Europe for its radioisotope product Ilumira (non-carrier-added lutetium-177), allowing the company to sell Lu-177 across the European Union (EU). The regulatory clearance enables access to a major market for…

Source: Medical Device Network